KHPG(SZ:002773) Ge Long Hui A P P·2025-12-25 11:16Core Viewpoint - Kanghong Pharmaceutical (002773.SZ) has received the drug registration certificate for Brexpiprazole tablets from the National Medical Products Administration, indicating a significant regulatory approval for a new treatment option for schizophrenia [1] Group 1: Company Developments - The drug registration certificate for Brexpiprazole tablets has been issued with certificate numbers 2025S03922 and 2025S03923, marking an important milestone for Kanghong Pharmaceutical [1] - Brexpiprazole is indicated for the treatment of schizophrenia, which is a critical area in mental health therapeutics [1] Group 2: Drug Mechanism - The exact mechanism of action for Brexpiprazole in treating schizophrenia is not fully understood, but it is believed to involve partial agonist activity at serotonin 5-HT1A and dopamine D2 receptors, along with antagonist activity at serotonin 5-HT2A receptors [1]